Scope Biosciences raises 500k€ investment from SHIFT and Oost NL

WAGENINGEN, October 23rd 2023 – Scope Biosciences B.V., a pioneer in CRISPR-Cas based molecular diagnostics and Venture Challenge Alumnus of 2020, announces a €500K investment round led by SHIFT Invest’s TTT fund and Oost NL.

Sencilia B.V. announces successful funding (€321k) of project 'Smartinfuus'

Venture Challenge alumnus (2023) Sencilia B.V. announced the successful funding of project 'SmartInfuus' in collaboration with the UMCG, University of Groningen, and Medical Innovation Xccelerator™ (MIX).  

IMcoMET takes home Next Frontier Award from Erasmus Enterprise

Venture Challenge alumnus (2019) IMcoMET, a company that develops a technology to improve skin cancer diagnostics, has been honored with the Next Frontier Award from 
winner photo

Praxa Sense secures investment round: Certified remote patient monitoring within reach

  Delft, July 2023 – The Dutch MedTech startup Praxa Sense, a company with leading solutions in remote patient monitoring, successfully secured an investment round to enter the commercialisation phase. This round is led by busin
Arthur and Leonard Signing

15-years LS@W by Chrétien Herben and Math Kohnen

LifeSciences@Work (LS@W) started in 2008, and now in 2023, it proudly celebrates its 15th anniversary. To mark this festive occasion, the special edition of the Health~Holland Update is devoted to the successes of LS@W throughout the years.

Financial Times - Europe’s Leading Start-up Hubs 2024

The Financial Times is seeking to rank accelerator and incubator programmes in Europe.
Financial Times

Faculty of Impact-call on Life Sciences & health

The Faculty of Impact program is aimed at researchers who want to achieve impact with their research and are interested in setting up their own company.

The deadline for the Venture Challenge Fall 2023 edition is approaching fast!

Thursday 13 July at 14:00 CEST the call closes The Venture Challenge is a 10-week programme to develop an initial idea – a breakthrough research result – into a solid business case.

STENTiT awarded with €12.5M funding from the European Innovation Council (EIC) Accelerator

  The EIC funding comprises €2.5M of grants to conduct first clinical trials and up to €10M in follow-up equity investment to extend the trials and work on market introduction.